SciELO - Scientific Electronic Library Online

 
vol.26 issue2On the track of stem cellsDetection of anti-gliadin and anti-transglutaminase antibodies in patients with possible celiac disease author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Hematología, Inmunología y Hemoterapia

Print version ISSN 0864-0289On-line version ISSN 1561-2996

Abstract

ARCE HERNANDEZ, Ada A. et al. Detection of antibodies to antigens of proteinase 3 (PR3) tumor differentiations and myeloperoxidase (MPO) in cases of promyelocytic leukemia. Rev Cubana Hematol Inmunol Hemoter [online]. 2010, vol.26, n.2, pp.23-27. ISSN 0864-0289.

ABSTRACT Promyelocytic leukemia (PML) subtype M3 represents the 5-15 % in the FAB classification of acute myeloid leukemias (AML). It is associated with the unique genetic features including the reciprocal t-translocation (15;17) (q22;q12). The mechanism of t is unknown. The myeloid leukemias express different tumoral differentiation antigens such as the proteinase 3 (PR 3) and myeloperoxidase (MPO) which are over-expressed in promyelocyte. It is involved in maturation and regulation of cell division. There is scarce information on the immune response of patients with PLM against tumor cells. In our paper we detected presence of antibodies to RP3 and MPO tumor differentiation antigens in different phases of disease treatment by indirect immunofluorescence. Anti-MPO and anti-PR3 antibodies were detected in those patients without treatment and in induction phase but not in the consolidation and maintenance, thus its potential usefulness as cellular differentiation markers.

Keywords : Tumoral differentiation antigens; promyelocytic leukemia; myeloperoxidase; proteinase-3.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License